TIGIT is a key inhibitory checkpoint receptor in lymphoma

Background PD-1 checkpoint blockade therapy (CBT) has greatly benefited patients with select solid tumors and lymphomas but has limited efficacy against diffuse large B-cell lymphoma (DLBCL). Because numerous inhibitory checkpoint receptors have been implicated in driving tumor-specific T cell dysfu...

Full description

Bibliographic Details
Published in:Journal for ImmunoTherapy of Cancer
Main Authors: Yuanyuan Zha, Xiufen Chen, James Godfrey, Girish Venkataraman, Justin P Kline, Aleksander Bagaev, Jovian Yu, Nicole Sunseri, Alan Cooper, Arina Varlamova, Dmitry Zarubin, Yuriy Popov, Connor Jacobson, Ekaterina Postovalova, Zhongmin Xiang, Krystle Nomie, Sravya Tumuluru, Sonali M Smith
Format: Article
Language:English
Published: BMJ Publishing Group 2023-06-01
Online Access:https://jitc.bmj.com/content/11/6/e006582.full

Internet

https://jitc.bmj.com/content/11/6/e006582.full

Similar Items